Skip to main content
< Back to news
Scott Huennekens, member of the Board of Directors of INBRAIN Neuroelectronics. Photo / INBRAIN
 10.12.2025

INBRAIN Neuroelectronics appoints Scott Huennekens as Chairman of the Board of Directors

INBRAIN Neuroelectronics, a medtech company based in the Barcelona Science Park and specializing in brain-computer interface (BCI-Tx) therapies with graphene technology, has appointed Scott Huennekens as Chairman of its Board of Directors. The addition of the U.S. executive comes at a critical stage for the company, which is accelerating the development of its next-generation BCI therapies ahead of upcoming trials and future commercialization for neurological disorders.

“Scott brings an exceptional track record in scaling medical technology companies and managing critical stages of growth,” said Carolina Aguilar, CEO and co-founder of INBRAIN. “His experience leading platforms ranging from medical imaging to surgical robotics and smart devices will be crucial as we advance into later-stage clinical development. It is an honour to welcome him at this defining moment for the company.”

Huennekens is a recognized figure in the medtech sector. With over two decades of experience, he has been a founder, executive, and advisor to several companies that have set trends in the healthcare industry. He has led two companies valued as “unicorns” and has contributed to the growth of around ten high-growth firms, with combined valuations exceeding $6 billion and technologies used by more than 20 million patients worldwide.

Among his most recent roles, he served as President and CEO of Verb Surgical, the joint venture created by Google and Johnson & Johnson with the goal of democratizing surgery through robotics, artificial intelligence, and advanced visualization. Previously, he led Volcano Corporation, taking the company from its founding to its IPO and subsequent acquisition by Philips. Under his leadership, Volcano became a global leader in image-guided therapy, surpassing $400 million in annual revenue and reaching a market capitalization close to $2 billion. He also served as President and CEO of Digirad Corporation, which later went public on Nasdaq.

“INBRAIN is developing the most promising BCI therapeutic platform in the sector,” said Huennekens. “Graphene offers a level of precision, biocompatibility, and signal quality that enables safer, smarter, and truly personalized therapies. It is a privilege to join Carolina and her team in the challenge of scaling this technology and bringing a new generation of neuroelectronic solutions to patients.”

Huennekens currently serves on the boards of NeuroPace, QuidelOrtho, Envista, Elucid, and Kardion, and previously chaired the U.S. Medical Device Manufacturers Association (MDMA). He holds a degree from the University of Southern California and an MBA from Harvard Business School.

» Link to the news [+]